Evidence map›Paper›PMID 30393127›Full record

ArticleThe Journal of nutritional biochemistry2019

Curcumin, but not curcumin-glucuronide, inhibits Smad signaling in TGFβ-dependent bone metastatic breast cancer cells and is enriched in bone compared to other tissues.

Andrew G Kunihiro, Julia A Brickey, Jennifer B Frye, Paula B Luis, Claus Schneider, Janet L Funk

Abstract read
In one paragraph

Article in The Journal of nutritional biochemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Regulation of Curcumin on Follicle Initiation Rate in Diminished Ovarian Reserve.Combinatorial chemistry & high throughput screening · 2025
    Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Dietary Bioactive Compounds and Breast Cancer.International journal of molecular sciences · 2023
    Article
  12. Muscle and Bone Defects in Metastatic Disease.Current osteoporosis reports · 2022
    Review
  13. Review
  14. Article
  15. Article
  16. Extracellular Vesicles in Human Milk.Pharmaceuticals (Basel, Switzerland) · 2021
    Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Andrew G KunihiroDepartment of Nutritional Sciences, University of Arizona, 1656 E. Mabel St, Medical Research Building Rm 418, Tucson, AZ 85719, USA. Electronic address: akunihiro@email.arizona.edu.
Julia A BrickeyDepartment of Medicine, University of Arizona, 1656 E. Mabel St, Medical Research Building Rm 418, Tucson, AZ 85719, USA. Electronic address: jabrickey@email.arizona.edu.
Jennifer B FryeDepartment of Medicine, University of Arizona, 1656 E. Mabel St, Medical Research Building Rm 418, Tucson, AZ 85719, USA. Electronic address: jabeisch@email.arizona.edu.
Paula B LuisDepartment of Pharmacology, Vanderbilt University, 23(rd) Ave S at Pierce RRB, Rm 514, Nashville, TN 37232-6602, USA. Electronic address: paula.b.luis@vanderbilt.edu.
Claus SchneiderDepartment of Pharmacology, Vanderbilt University, 23(rd) Ave S at Pierce RRB, Rm 514, Nashville, TN 37232-6602, USA. Electronic address: claus.schneider@vanderbilt.edu.
Janet L FunkDepartment of Nutritional Sciences, University of Arizona, 1656 E. Mabel St, Medical Research Building Rm 418, Tucson, AZ 85719, USA; Department of Medicine, University of Arizona, 1656 E. Mabel St, Medical Research Building Rm 418, Tucson, AZ 85719, USA. Electronic address: jfunk@email.arizona.edu.
University of Arizona · USVanderbilt University · US

Funding

Translational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2002 to 2026
$29.9M
Oxidative activation of the dietary cancer chemopreventive agent curcuminR01AT006896 · NCCIH · VANDERBILT UNIVERSITY · PI SCHNEIDER, CLAUS · 2013 to 2017
$2.2M
Exploiting the Tumor Microenvironment to Block Breast Cancer Bone MetastasisR01CA174926 · NCI · UNIVERSITY OF ARIZONA · PI FUNK, JANET L · 2014 to 2018
$1.6M
Curcuma longa L. in Rheumatoid Arthritis (CLaRA): Clinical Planning StudyR34AT007837 · NCCIH · UNIVERSITY OF ARIZONA · PI FUNK, JANET L · 2013 to 2015
$737k
Bone-specific deglucuronidation of turmeric-derived curcuminoids for the treatment of osteolytic diseaseF31AT009938 · NCCIH · UNIVERSITY OF ARIZONA · PI KUNIHIRO, ANDREW GEORGE KENRO · 2018 to 2019
$61k
NCCIH NIH HHS F31 AT009938NCCIH NIH HHS R01 AT006896NCCIH NIH HHS R34 AT007837NCI NIH HHS R01 CA174926NIDDK NIH HHS P30 DK058404
6 · The paper itself

Abstract

Breast cancer (BCa) bone metastases (BMETs) drive osteolysis via a feed-forward loop involving tumoral secretion of osteolytic factors (e.g., PTHrP) induced by bone-matrix-derived growth factors (e.g., TGFβ). In prior experiments, turmeric-derived curcumin inhibited in vivo BMET progression and in vitro TGFβ/Smad-signaling in a TGFβ-stimulated PTHrP-dependent human xenograft BCa BMET model (MDA-SA cells). However, it is unclear whether curcumin or curcumin-glucuronide mediates in vivo protection since curcumin-glucuronide is the primary circulating metabolite in rodents and in humans. Thus, effects of curcumin vs. curcumin-glucuronide on Smad-dependent TGFβ signaling were compared in a series of BCa cell lines forming TGFβ-dependent BMET in murine models, and tissue-specific metabolism of curcumin in mice was examined by LC-MS. While curcumin inhibited TGFβ-receptor-mediated Smad2/3 phosphorylation in all BCa cells studied (human MDA-SA, MDA-1833, MDA-2287 and murine 4T1 cells), curcumin-glucuronide did not. Similarly, curcumin, but not curcumin-glucuronide, blocked TGFβ-stimulated secretion of PTHrP from MDA-SA and 4T1 cells. Because the predominant serum metabolite, curcumin-glucuronide, lacked bioactivity, we examined tissue-specific metabolism of curcumin in mice. Compared to serum and other organs, free curcumin (both absolute and percentage of total) was significantly increased in bone, which was also a rich source of enzymatic deglucuronidation activity. Thus, curcumin, and not curcumin-glucuronide, appears to inhibit bone-tropic BCa cell TGFβ-signaling and to undergo site-specific activation (deconjugation) within the bone microenvironment. These findings suggest that circulating curcumin-glucuronide may act as a prodrug that preferentially targets bone, a process that may contribute to the bone-protective effects of curcumin and other highly glucuronidated dietary polyphenols.

Indexed as

Administration, OralAnimalsAntineoplastic Agents, PhytogenicBone NeoplasmsBreast NeoplasmsCell Line, TumorCurcuminFemaleGlucuronidesHumansMiceMice, Inbred C57BLParathyroid Hormone-Related ProteinSignal TransductionSmad ProteinsTransforming Growth Factor betaAntineoplastic Agents, PhytogenicCurcumincurcumin glucuronideGlucuronidesParathyroid Hormone-Related ProteinSmad ProteinsTransforming Growth Factor betaBone metastasisBreast cancerCurcuminGlucuronideTGFβ

Identifiers

PMID30393127
PMCPMC6296872
OpenAlexW2896168487

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.